PACS Group, Inc. (PACS)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $7.67B
Last updated: Nov 17, 2026 at 11:06 AM ET
PACS Group, Inc. (PACS) P/E Ratio & Valuation Multiples
PACS Group (PACS) trades at 21.0x trailing earnings and 1.4x sales. Its forward P/E is 18.3x. The median P/E across 12 similar companies is 24.2x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 14.8% higher over the next year. Its free cash flow yield is 0.1%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 21.0x |
| Forward P/E | 18.3x |
| Price to sales | 1.4x |
| Price to book | 6.4x |
| EV/EBITDA | 15.8x |
| Price to FCF | 941.4x |
|---|---|
| EV/FCF | 960.4x |
| PEG | 1.2 |
| FCF yield | 0.1% |
As of Nov 17, 2026
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PACS
What is PACS's forward P/E ratio?
PACS Group has a forward P/E ratio of 18.3x.
Is PACS stock overvalued?
GNG's valuation label for PACS is Fairly valued. Its P/E of 21.0x compares with a median of 24.2x across 12 similar companies.
What is PACS's price to sales ratio?
PACS Group has a price to sales ratio of 1.4x.
What is PACS's PEG ratio?
PACS Group has a PEG ratio of 1.2.
PACS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors